ProPhase Labs, Inc. (NASDAQ: PRPH) saw its shares lose some strength Wednesday, as the next-generation biotech, genomics, and diagnostics company, reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. ...